Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines

Biomaterials

Volumn 33, Issue 8, 2012, Pages 2492-2507

  Jinturkar, Kaustubh A ^a   Anish, Chakkumkal ^b   Kumar, Mukesh K ^a   Bagchi, Tamishraha ^a   Panda, Amulya K ^b   Misra, Ambikanandan R ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Chemo sensitization; Cytotoxicity; Docetaxel; Etoposide; P53

Indexed keywords

ANNEXINS; AVERAGE SIZE; CASCADE IMPACTORS; CATIONIC LIPOSOMES; CELL LINES; CHEMO-SENSITIZATION; DEPOSITION PATTERNS; DOCETAXEL; DRUG RESISTANCE; DRY POWDER INHALER; ETOPOSIDE; FINE PARTICLES; IN-VITRO; INTRACELLULAR UPTAKE; LIPOPLEXES; LIPOSOMAL FORMULATION; LUNG CANCER; LUNG CANCER CELLS; NEW STRATEGY; NON SMALL CELL LUNG CANCER; P53; P53 FUNCTION; PRE-TREATMENT; SUSTAINED DRUG RELEASE; TUMOR SUPPRESSOR GENES;

BIOLOGICAL ORGANS; CELL CULTURE; CELL DEATH; CYTOTOXICITY; DISEASES; GENES; LIPOSOMES; METEOROLOGICAL INSTRUMENTS; OPTIMIZATION; PHOSPHOLIPIDS; ZETA POTENTIAL;

DRUG PRODUCTS;

DOCETAXEL; ETOPOSIDE; LIPOPLEX; P53 LIPOPLEX; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL ENCAPSULATION; CHEMOSENSITIZATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANNEXIN A5; BETA-GALACTOSIDASE; CELL DEATH; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; COUMARINS; DEOXYRIBONUCLEASES; ELECTROPHORESIS, AGAR GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ETOPOSIDE; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FREEZE DRYING; HUMANS; INTRACELLULAR SPACE; LIPOSOMES; LUNG NEOPLASMS; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; STATIC ELECTRICITY; TAXOIDS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855826986     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.067     Document Type: Article

References (38)

1. National Cancer Institute, U.S. National Institutes of Health - Lung cancer. Accessed on 26th June 2011. Available from: URL:. http://www.cancer.gov/cancertopics/types/lung.
2. Sengupta S., Tyagi P., Velpandian T., Gupta Y.K., Gupta S.K. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 2000, 42:459-464.
3. Herbst R., Khuri F. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 2003, 29:407-415.
4. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomed 2008, 3:761-776.
5. Verma I.M., Somia N. Gene therapy: promises, problems and prospects. Nature 1997, 389:239-242.
6. Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. JGene Med 2007, 9:833-842.
7. Deonarain M. Ligand-targeted receptor-mediated vectors for gene delivery. Exp Opin Ther Pat 1998, 8:53-69.
8. Yamashita Y., Shimada M., Hasegawa H., Minagawa R., Rikimaru T., Hamatsu T., et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001, 61:1005-1012.
9. Choi S., Jin S., Lee M., Lim S., Park J., Kim B., et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm 2008, 68:545-554.
10. Wiradharma N., Tong Y.W., Yang Y.Y. Self-assembled oligopeptide nanostructures for codelivery of drug and gene with synergistic therapeutic effect. Biomaterials 2009, 30:3100-3109.
11. Wang Y., Gao S., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
12. Li R., Hehlman R., Sachs R., Duesberg P. Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genet Cytogenet 2003, 163:44-56.
13. Pirollo K.F., Hao Z., Rait A., Jang Y.J., Fee W.E., Ryan P., et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997, 14:1735-1746.
14. Ruley H.E. p53 and response to chemotherapy and radiotherapy. Important Adv Oncol 1996, 37-56.
15. Chiarugi V., Magnelli L., Gallo O. Cox-2 iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998, 2:715-719.
16. Pirollo K.F., Xu L., Chang E.H. Non-viral gene delivery for p53. Curr Opin Mol Ther 2000, 2:168-175.
17. Sidransky D., Hollstein M. Clinical implications of the p53 gene. Annu Rev Med 1996, 47:285-301.
18. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. JControl Release 2001, 74:115-128.
19. Xu L., Pirollo K.F., Tang W.H., Rait A., Chang E.H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999, 10:2941-2952.
20. Zou Y., Zong G., Ling Y.H., Soler R.P. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther 2000, 7:683-696.
21. Swisher S.G., Roth J.A., Komaki R., Gu J., Lee J.J., Hicks M., et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003, 9:93-101.
22. Logunov D.Y., Ilyinskaya G.V., Cherenova L.V., Verhovskaya L.V., Shmarov M.M., Chumakov P.M., et al. Restoration of p53 tumor-suppressor activity in human tumor cells invitro and in their xenografts invivo by recombinant avian adenovirus CELO-p53. Gene Ther 2004, 11:79-84.
23. Liu F., Shollenberger L.M., Huang L. Non-immunostimulatory nonviral vectors. FASEB J 2004, 18:1779-1781.
24. Pakunlu R.I., Wang Y., Tsao W., Pozharov V., Cook T.J., Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 2004, 64:6214-6224.
25. Wu Y.L., Mehew J.W., Heckman C.A., Arcinas M., Boxer L.M. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001, 20:240-251.
26. Mu L., Feng S.S. Fabrication, characterization and invitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique\with lipid/cholesterol emulsifiers. JControl Release 2001, 76:239-254.
27. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
28. Physical tests & determinations <601> aerosols, Nasal Sprays, Metered-dose inhalers, & dry powder inhalers. In United States Pharmacopoeia 34 - National Formulary 29, 2011 -p. 218-238.
29. Zhang H., Ozaki I., Mizuta T., Matsuhashi S., Yoshimura T., Hisatomi A., et al. Beta1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen activated protein kinase dependent pathway. Cancer 2002, 95:896-906.
30. Stefanelli C., Bonvita F., Stanic I., Pignatti C., Farruggia G., Masotti L., et al. Inhibition of etoposide-induced apoptosis with peptide aldehyde inhibitors of proteasome. Biochem J 1998, 332:661-665.
31. Maitani Y., Aso Y., Yamada A., Yoshioka S. Effect of sugars on storage stability of lyophilized liposome/DNA complexes with high transfection efficiency. Int J Pharm 2008, 356:69-75.
32. Hong M.S., Lim S.J., Oh Y.K., Kim C.K. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. JPharm Pharmacol 2002, 54:51-58.
33. Li S.D., Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 2006, 3:579-588.
34. Li S.D., Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci 2006, 1082:1-8.
35. Frank D.K., Frederick M.J., Liu T.J., Clayman G.L. Bystander effect in the adenovirus-mediated wildtype p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin Cancer Res 1998, 4:2521-2528.
36. Rao R.D., Markovic S.N., Anderson P.M. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 2003, 4:239-250.
37. Zou Y., Tornos C., Qiu X., Lia M., Soler R.P. p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin Cancer Res 2007, 13:4900-4908.
38. Anabousi S., Bakowsky U., Schneider M., Huwerc H., Lehr C.M., Ehrhardt C. Invitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 2006, 29:367-374.